Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence

Other OA: closed CC0 ⤵ 29 in-corpus citations
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Ovarian endometriomas with higher cyclooxygenase-2 expression were associated with an increased risk of recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Cyclooxegenase-2 expression was evaluated by immunohistochemistry in endometrioma tissue samples taken from 109 patients, of whom 53 had recurrence by 30 months after surgery and 56 did not. Cyclooxegenase-2 overexpression, along with previous medical treatment of endometriosis and the presence of adhesion, is predictive of recurrence of ovarian endometrioma within 30 months after surgery, with a resultant sensitivity of 72.5% and a specificity of 72.4%, suggesting that there are intrinsic and identifiable biomarkers that confer recurrence risk.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cyclooxygenase 2 Endometriosis Endometriosis Ovarian Diseases Ovarian Diseases Adult Adult Biomarkers Biomarkers Biomarkers Case-Control Studies Case-Control Studies Cyclooxygenase 2 Cyclooxygenase 2 Endometriosis Endometriosis Endometriosis Female Female Gene Expression Regulation, Enzymologic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (28)

Source provenance

europepmc
last seen: 2026-10-21T06:16:17.486033+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:10.907216+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK